We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic

News   Jul 01, 2013

 
Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic
 
 
 

RELATED ARTICLES

PCR Assay Helps ID Sarcoma Mutations

News

Sarcomas are rare tumors that are often misdiagnosed. A report in the Journal of Molecular Diagnostics describes a new assay, anchored multiplex PCR (AMP)-based targeted next-generation-sequencing (NGS), that is better able to identify genetic diagnostic markers of the cancer.

READ MORE

Breast Cancer Vulnerability Could Be Exploited by Future Targeted Drugs

News

Researchers have identified a vulnerability in some breast cancer cells of a certain type – called triple negative breast cancer – that could be exploited by future targeted drugs.

READ MORE

Scientists Develop Platform to Kill Cancer Cells

News

For the first time ever, scientists have shown that a hybrid nanomaterial based on magnetite-gold particles can serve as a universal platform to both detect cancer cells anywhere in the body and to complete targeted deliveries of drugs to these cells.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE